Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer
|ClinicalTrials.gov Identifier: NCT00527982|
Recruitment Status : Terminated (Termination due to poor accrual.)
First Posted : September 11, 2007
Results First Posted : April 20, 2011
Last Update Posted : December 6, 2012
- To examine the effect of celecoxib treatment on histological response, markers of proliferation (Ki-67), and apoptosis. Secondary endpoints include time to second primary or recurrence and survival.
- To examine the toxicity associated with celecoxib administration in patients with previously treated Head and Neck Head and neck squamous cell carcinomas (HNSCC)or Non-small-cell lung carcinoma (NSCLC).
|Condition or disease||Intervention/treatment||Phase|
|Head and Neck Cancer Lung Cancer||Drug: Celecoxib||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Celecoxib as Adjuvant Biologic Therapy in Patients With Early Stage Head and Neck and Lung Cancer|
|Study Start Date :||September 2005|
|Primary Completion Date :||September 2008|
|Study Completion Date :||September 2008|
Experimental: Celecoxib treatment
600 mg orally (PO) daily
600 mg by mouth daily for a total of 12 months.
Other Name: Celebrex
|No Intervention: No treatment|
- Histological Responses [ Time Frame: Baseline to 12 months ]Number of patients with histological response based on changes in bronchoscopies from baseline to 12 months.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00527982
|United States, Texas|
|U.T.M.D. Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Waun K. Hong, MD||M.D. Anderson Cancer Center|